Should you buy Boston Scientific stock now?
The technical signal for Boston Scientific is currently NEUTRAL. Boston Scientific trades at $49.97 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is positive (bullish trend) at 0.484 with rising momentum (signal: -0.184); RSI is at 59.0 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $62.69 points to 25.5% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Boston Scientific stock?
The average analyst price target for Boston Scientific is $62.69. The current price is $49.97, which gives an upside of 25.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $56.42 and $68.96.
Is Boston Scientific a dividend stock?
No, Boston Scientific does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Boston Scientific stock?
Boston Scientific is rated as a stock with moderate risk. the annual standard deviation is 36.1%, which classifies the stock as moderate risk.
Is Boston Scientific overvalued?
No, Boston Scientific is considered undervalued based on the analyst price target (25.5% upside). Boston Scientific has the following valuation ratios: a P/E ratio of 19.9 (moderately valued), a P/S ratio of 3.4, a P/B ratio of 2.7. The analyst price target suggests that the stock is undervalued by 25.5%.
Is Boston Scientific overbought?
No, Boston Scientific is not overbought. RSI is at 59.0 (neutral zone). The technical indicators show: RSI is at 59.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 10.8% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Boston Scientific earnings report?
The date of the next earnings report for Boston Scientific has not been published yet. Check the company's investor calendar for updates.
Is Boston Scientific shorted?
Yes, Boston Scientific is shorted with 1.9% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Boston Scientific stock?
Yes, insiders are net buyers of Boston Scientific – they are buying more shares than they are selling. Over the last 3 months, insiders have made 9 purchases and 1 sales. On a net basis, 12,768,013 $ worth of shares were bought. Across the last 20 reported transactions, the split is 10 purchases and 10 sales, with a net 11,227,455 $ bought. Active buyers include Habiger David C, Mahoney Michael F, LUDWIG EDWARD J and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Boston Scientific a good stock?
Based on our total score, Boston Scientific is rated as a mediocre stock with a total score of 50 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 64/100, Quality: 77/100, Momentum: 9/100. In addition: analysts see 25.5% upside to the price target; technical signal: Hold. Whether Boston Scientific is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Boston Scientific stock?
The outlook for Boston Scientific based on current data: the average analyst price target is $62.69 (+25.5%); the P/E ratio is 19.9 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Boston Scientific stock rising?
Boston Scientific is rising right now. The technical indicators show: the price is 10.8% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Boston Scientific go?
The average analyst price target for Boston Scientific is $62.69, which corresponds to a potential gain of 25.5% from the current price of $49.97. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Boston Scientific fall?
We lack enough history to give a specific floor for Boston Scientific. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Boston Scientific do?
Boston Scientific Corporation laver og sælger medicinsk udstyr til hospitaler over hele verden. De tjener penge på at udvikle avancerede instrumenter, som læger bruger til operationer og behandlinger. Virksomheden driver to hovedområder: MedSurg og Cardiovascular.
Boston Scie... The company belongs to the Sundhed sector, more specifically the Medicinprodukter industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Boston Scientific as an investment.
Did Boston Scientific raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Boston Scientific. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Boston Scientific making money or losing money?
Yes, Boston Scientific is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 17.5% — which is solid. The operating margin (profit before interest and taxes) is 22.9%. At a P/E ratio of 19.9, you currently pay 19.9 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Boston Scientific go bankrupt?
The bankruptcy risk of Boston Scientific is rated as low. Altman Z2 (a model for assessing financial distress) is 2.72 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 80% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Boston Scientific have a lot of debt?
No, Boston Scientific has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 80%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Boston Scientific service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 12.0x, and net debt equals 2.1 years of earnings (EBITDA).
